Therefore, in view of the limitations of this study, the need for high methodological quality, good experimental design, and large sample size RCTs are needed to study the clinical efficacy and safety of CKI in the treatment of NSCLC. This evidence concerns the gene CHKA and non-small cell lung carcinoma.